CO2021014873A2 - Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina - Google Patents

Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina

Info

Publication number
CO2021014873A2
CO2021014873A2 CONC2021/0014873A CO2021014873A CO2021014873A2 CO 2021014873 A2 CO2021014873 A2 CO 2021014873A2 CO 2021014873 A CO2021014873 A CO 2021014873A CO 2021014873 A2 CO2021014873 A2 CO 2021014873A2
Authority
CO
Colombia
Prior art keywords
thiazoline
polymorphs
manufacturing methods
antihyperalgesic
compound
Prior art date
Application number
CONC2021/0014873A
Other languages
English (en)
Inventor
Scott L Dax
Original Assignee
Cersci Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cersci Therapeutics Inc filed Critical Cersci Therapeutics Inc
Publication of CO2021014873A2 publication Critical patent/CO2021014873A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/08—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D277/12—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/18—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

En el presente documento se proporcionan métodos para preparar un Compuesto 1 antihiperalgésico de tiazolina y polimorfos del mismo. Los métodos descritos en el presente documento usan reactivos económicos y son capaces de proporcionar el Compuesto 1 en cantidades a escala comercial. También se proporcionan composiciones farmacéuticas del Compuesto 1 adecuadas para la administración humana. (I)
CONC2021/0014873A 2019-05-10 2021-11-03 Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina CO2021014873A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962846096P 2019-05-10 2019-05-10
PCT/US2020/021883 WO2020231496A1 (en) 2019-05-10 2020-03-10 Manufacturing methods and polymorphs of a thiazoline anti-hyperalgesic agent

Publications (1)

Publication Number Publication Date
CO2021014873A2 true CO2021014873A2 (es) 2022-01-28

Family

ID=70057356

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014873A CO2021014873A2 (es) 2019-05-10 2021-11-03 Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina

Country Status (14)

Country Link
US (2) US11161826B2 (es)
EP (1) EP3966200A1 (es)
JP (1) JP2022531453A (es)
KR (1) KR20220006539A (es)
CN (1) CN113874360A (es)
AU (1) AU2020275683A1 (es)
BR (1) BR112021022478A2 (es)
CA (1) CA3136102A1 (es)
CL (1) CL2021002855A1 (es)
CO (1) CO2021014873A2 (es)
IL (1) IL287776A (es)
MX (1) MX2021013524A (es)
SG (1) SG11202110561XA (es)
WO (1) WO2020231496A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4342469A3 (en) 2019-05-10 2024-06-19 Deciphera Pharmaceuticals, LLC Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2581063B1 (fr) 1985-04-30 1987-07-17 Chauvin Blache Lab Amino-2 thiazoles n-substitues, leur procede de preparation et leur application en therapeutique
US5840739A (en) 1992-11-16 1998-11-24 University Of Florida Research Foundation, Inc. Thiazoline acid derivatives
PE20050159A1 (es) 2003-05-27 2005-04-19 Vertex Pharma Derivados de acido 3-[2-(3-amino-2-oxo-2h-piridin-1-il)-acetilamino]-4-oxo-pentanoico como inhibidores de caspasa
GB0508463D0 (en) 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
CN101528728B (zh) * 2006-08-03 2014-01-01 罗塔药品股份有限公司 6-1h-咪唑并-喹唑啉和喹啉衍生物，镇痛剂和抗炎剂
TW200826937A (en) 2006-11-01 2008-07-01 Astrazeneca Ab New use
NL2003786C2 (en) 2009-11-11 2010-07-30 Medner B V COMPOSITION FOR TOPICAL APPLICATION, USES THEREOF, APPLICATOR DEVICE AND KIT OF PARTS.
CN102858176A (zh) * 2010-03-10 2013-01-02 加林制药公司 镇痛化合物、组合物及其应用
EP3070084A1 (en) 2015-03-18 2016-09-21 Rottapharm Biotech S.r.l. New fyn kinase inhibitors
JP7104702B2 (ja) 2016-12-01 2022-07-21 プロメガ コーポレイション ５，５－二置換ルシフェリン及びルシフェラーゼ系アッセイにおけるそれらの使用

Also Published As

Publication number Publication date
CN113874360A (zh) 2021-12-31
CL2021002855A1 (es) 2022-06-17
MX2021013524A (es) 2021-12-10
EP3966200A1 (en) 2022-03-16
US11161826B2 (en) 2021-11-02
AU2020275683A1 (en) 2021-11-04
WO2020231496A1 (en) 2020-11-19
US20220267285A1 (en) 2022-08-25
KR20220006539A (ko) 2022-01-17
US20200354328A1 (en) 2020-11-12
SG11202110561XA (en) 2021-10-28
IL287776A (en) 2022-01-01
JP2022531453A (ja) 2022-07-06
CA3136102A1 (en) 2020-11-19
BR112021022478A2 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
DOP2023000016A (es) Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos
CL2019002777A1 (es) Compuestos que inhiben la proteína mcl-1.
UY37201A (es) Nuevos derivados de pirazolopirimidina
CR20170116A (es) Compuestos que inhiben la proteina mcl-1
UY37098A (es) Moduladores de ror-gamma
CO2020001242A2 (es) Dihidrooxadiazinonas
UY37460A (es) 1,2,4-triazolonas con anelación en 4 y 5
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
ECSP19051352A (es) Inhibidores selectivos de jak1
CL2020000363A1 (es) Inhibidores macrocíclicos de mcl-1 y métodos de uso.
UY35293A (es) Isotiazoles sustituidos con amino
BR112017000169A2 (pt) picolinamidas macrocíclicas como fungicidas
MX2018010032A (es) Formulaciones de antagonista de il-6 y sus usos.
CL2020000944A1 (es) Compuestos bicíclicos y métodos de utilización de los mismos.
UY38228A (es) Compuestos de triazolopirimidina y su uso en el tratamiento del cáncer
CL2015002835A1 (es) Nuevos derivados de piridina
DOP2019000275A (es) Nuevos derivados de pirazol bicíclicos
MX2020003495A (es) Derivados de acido boronico y sintesis de los mismos.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
DOP2017000018A (es) [1,2,4]triazolo[4,3-b]piridazinas para su uso en el tratamiento de enfermedades proliferativas
CO2020003475A2 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos
UY38809A (es) Derivados de 3,6-diamino-piridazin-3ilo, composiciones farmacéuticas que los contienen y sus usos como agentes proapoptóticos
DOP2018000083A (es) NUEVOS DERIVADOS DE IMIDAZO[4,5-b]PIRIDINA, UN PROCESO PARA SU PREPARACIÓN Y COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN
NI202000031A (es) Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3
CO2021014873A2 (es) Métodos de fabricación y polimorfos de un agente antihiperalgésico de tiazolina